Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
interferon gamma-1b
|
| gptkbp:administrativeDivision |
three times a week
|
| gptkbp:clinicalTrials |
Phase III
treatment of infections treatment of immune deficiencies |
| gptkbp:contraindication |
anemia
thrombocytopenia hypersensitivity to interferon gamma-1b leukopenia |
| gptkbp:date |
1990-11-09
|
| gptkbp:dosageForm |
lyophilized powder for reconstitution
|
| gptkbp:drugInterdiction |
available
excreted in urine metabolized in the liver immunosuppressants subcutaneous absorption biologic response modifier other interferons |
| gptkbp:endOfLife |
approximately 2-3 hours
|
| gptkbp:formulation |
powder for injection
|
| gptkbp:healthcare |
avoid live vaccines
inform healthcare provider of all medications report any signs of infection |
| https://www.w3.org/2000/01/rdf-schema#label |
Actimmune
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:mandates |
treatment of chronic granulomatous disease
treatment of severe malignant osteopetrosis |
| gptkbp:manufacturer |
InterMune,_Inc.
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:notableFeature |
gptkb:Actimmune
|
| gptkbp:patentExpiration |
2010-11-09
|
| gptkbp:relatedPatent |
infections
immunodeficiency autoimmune disorders |
| gptkbp:renovated |
dilute with sterile water for injection
|
| gptkbp:route |
subcutaneous injection
|
| gptkbp:safetyFeatures |
monitor for autoimmune disorders
monitor for cardiovascular events monitor for psychiatric symptoms monitor for thyroid function not recommended during breastfeeding not recommended during pregnancy |
| gptkbp:sideEffect |
fatigue
headache nausea injection site reactions flu-like symptoms |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
modulates_immune_response
|
| gptkbp:usedFor |
chronic granulomatous disease
severe malignant osteopetrosis |